Where Arcus Biosciences Stands With Analysts
Portfolio Pulse from Benzinga Insights
Arcus Biosciences (NYSE:RCUS) has received mixed analyst ratings over the past three months, with a current average price target of $26.4, down from $28. Analysts have varied opinions, with some maintaining 'Outperform' ratings and others lowering to 'Neutral'. The company has shown significant revenue growth but faces challenges with net margin and ROA.
October 21, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Arcus Biosciences has received mixed analyst ratings, with a current average price target of $26.4, down from $28. Analysts have varied opinions, with some maintaining 'Outperform' ratings and others lowering to 'Neutral'. The company has shown significant revenue growth but faces challenges with net margin and ROA.
The mixed analyst ratings indicate uncertainty in the market's perception of Arcus Biosciences. The lowered average price target suggests a cautious outlook, but the company's strong revenue growth provides a positive counterbalance. The challenges in net margin and ROA may weigh on investor sentiment, resulting in a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100